The company recently received market authorization from the Indian drug regulator for its drug Vorasidenib, a first-in-class, ...

The MarketWatch News Department was not involved in the creation of this content.-- Voranigo(R) has been awarded the Prix Galien USA, the Prix Galien Poland and the Prix Galien Br ...

Servier India to launch Vorasidenib (Voranigo), a targeted therapy for patients with Grade 2 IDH-mutant glioma ...

Suresnes (France), May 13, 2014 – Servier today announced that they have signed a strategic global collaboration agreement with Novartis to develop and commercialize a series of novel drugs candidates ...

International pharmaceutical group Servier has expanded its partnership with Google Cloud to accelerate the research and development (R&D) of pharmaceuticals. Servier and Google Cloud have entered ...

Servier has opened a site in Kendall Square and staffed it with people from Biogen and the University of Massachusetts to find R&D and licensing opportunities. News of the office opening comes shortly ...

TIBSOVO is a targeted therapy that works against an abnormal protein created by a mutation in the IDH1 gene. This abnormal protein plays an important role in the development of AML because it prevents ...

Servier will partner with Pieris Pharmaceuticals to co-develop Pieris’ preclinical dual-checkpoint inhibitor PRS-332 and up to seven other immuno-oncology bispecific drug candidates in a collaboration ...

After cancer drug Tibsovo hit a hurdle in Europe while in the hands of former developer Agios Pharmaceuticals, Servier, the drug’s new owner, has been looking for a late-stage trial win to reach the ...

Servier India receives CDSCO approval for Vorasidenib (Voranigo), a brain cancer drug for Grade 2 IDH-mutant glioma patients.

FILE - In this May 21, 2013 file photo, Jacques Servier, founder of Servier Laboratories, is pictured during the opening of the trial of the so-called Mediator case, a drug allegedly linked to ...

Servier, an independent international pharmaceutical group governed by a foundation, today announced that Voranigo® (vorasidenib) has been awarded the inaugural 2025 Prix Galien Bridges Award for Best ...